RM-MET / Metabolic and incretin signalling
Pemvidutide
Also known as: ALT-801
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Pemvidutide is the current name for ALT-801, an investigational long-acting glucagon/GLP-1 receptor co-agonist.
Evidence position
Published randomized phase 2b results support Grade B. Its record is still investigational and does not have an approved finished-product comparator.
What the record does not establish
A name match does not prove structural identity, conjugation, concentration, stability or the analytical quality of a separately sourced sample.
Sources
- 01Pemvidutide phase 1 registry recordClinicalTrials.gov
- Shows
- Official ALT-801/Pemvidutide aliases, study design and intervention record
- Does not show
- A registry entry does not establish positive results, approval or lot quality
- 02Pemvidutide in MASH: IMPACT phase 2bPubMed
- Shows
- Randomized, double-blind phase 2b human trial results
- Does not show
- Results are protocol- and formulation-specific and do not authenticate outside material
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.Journal of hepatology / 2025 JanPMID 39002641 / DOI 10.1016/j.jhep.2024.07.006
- Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides / 2025 MayPMID 40081498 / DOI 10.1016/j.peptides.2025.171380
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.Indian journal of endocrinology and metabolism / 2024 Sep-OctPMID 39676791 / DOI 10.4103/ijem.ijem_442_23
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet (London, England) / 2025 Dec 6PMID 41237796 / DOI 10.1016/S0140-6736(25)02114-2
- Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.Journal of cachexia, sarcopenia and muscle / 2025 DecPMID 41362110 / DOI 10.1002/jcsm.70147
CLINICALTRIALS.GOV / FOUND RECORDS
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)COMPLETED / PHASE2 / Altimmune, Inc.NCT05989711 / DIRECT intervention MATCH: Pemvidutide
- RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)RECRUITING / PHASE2 / Altimmune, Inc.NCT07009860 / DIRECT intervention MATCH: Pemvidutide
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)COMPLETED / PHASE1 / Altimmune, Inc.NCT05292911 / DIRECT intervention MATCH: Pemvidutide
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityCOMPLETED / PHASE1 / Altimmune, Inc.NCT04561245 / DIRECT intervention MATCH: Pemvidutide
- Pemvidutide (ALT-801) DDI Study in Healthy VolunteersCOMPLETED / PHASE1 / Altimmune, Inc.NCT04972396 / DIRECT intervention MATCH: Pemvidutide